vs
PHIBRO ANIMAL HEALTH CORP（PAHC）とUiPath, Inc.（PATH）の財務データ比較。上の社名をクリックして会社を切り替えられます
UiPath, Inc.の直近四半期売上が大きい（$411.1M vs $373.9M、PHIBRO ANIMAL HEALTH CORPの約1.1倍）。UiPath, Inc.の純利益率が高く（48.4% vs 7.3%、差は41.0%）。PHIBRO ANIMAL HEALTH CORPの前年同期比売上増加率が高い（20.9% vs 15.9%）。UiPath, Inc.の直近四半期フリーキャッシュフローが多い（$25.1M vs $8.3M）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs 0.7%）
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
UiPath Inc.は人工知能（AI）、自律型オートメーションおよびオーケストレーションソフトウェアを開発するグローバルソフトウェア企業です。同社の製品は複雑な業務プロセスやワークフローを自動化するAIエージェントの構築・管理に対応し、各業界の業務効率向上を支援しています。
PAHC vs PATH — 直接比較
損益計算書 — Q2 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $373.9M | $411.1M |
| 純利益 | $27.5M | $198.8M |
| 粗利率 | 35.5% | 83.3% |
| 営業利益率 | 13.5% | 3.2% |
| 純利益率 | 7.3% | 48.4% |
| 売上前年比 | 20.9% | 15.9% |
| 純利益前年比 | 762.1% | 1966.2% |
| EPS（希薄化後） | $0.67 | $0.37 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $373.9M | $411.1M | ||
| Q3 25 | $363.9M | $361.7M | ||
| Q2 25 | $378.7M | $356.6M | ||
| Q1 25 | $347.8M | $423.6M | ||
| Q4 24 | $309.3M | $354.7M | ||
| Q3 24 | $260.4M | $316.3M | ||
| Q2 24 | $273.2M | $335.1M | ||
| Q1 24 | $263.2M | $405.3M |
| Q4 25 | $27.5M | $198.8M | ||
| Q3 25 | $26.5M | $1.6M | ||
| Q2 25 | $17.2M | $-22.6M | ||
| Q1 25 | $20.9M | $51.8M | ||
| Q4 24 | $3.2M | $-10.7M | ||
| Q3 24 | $7.0M | $-86.1M | ||
| Q2 24 | $752.0K | $-28.7M | ||
| Q1 24 | $8.4M | $33.9M |
| Q4 25 | 35.5% | 83.3% | ||
| Q3 25 | 32.9% | 82.2% | ||
| Q2 25 | 29.0% | 82.1% | ||
| Q1 25 | 30.1% | 84.8% | ||
| Q4 24 | 32.9% | 82.0% | ||
| Q3 24 | 32.1% | 80.0% | ||
| Q2 24 | 31.9% | 83.5% | ||
| Q1 24 | 30.2% | 86.8% |
| Q4 25 | 13.5% | 3.2% | ||
| Q3 25 | 14.1% | -5.6% | ||
| Q2 25 | 8.9% | -4.6% | ||
| Q1 25 | 9.6% | 7.9% | ||
| Q4 24 | 8.3% | -12.2% | ||
| Q3 24 | 6.8% | -32.7% | ||
| Q2 24 | 6.7% | -14.8% | ||
| Q1 24 | 7.6% | 3.7% |
| Q4 25 | 7.3% | 48.4% | ||
| Q3 25 | 7.3% | 0.4% | ||
| Q2 25 | 4.5% | -6.3% | ||
| Q1 25 | 6.0% | 12.2% | ||
| Q4 24 | 1.0% | -3.0% | ||
| Q3 24 | 2.7% | -27.2% | ||
| Q2 24 | 0.3% | -8.6% | ||
| Q1 24 | 3.2% | 8.4% |
| Q4 25 | $0.67 | $0.37 | ||
| Q3 25 | $0.65 | $0.00 | ||
| Q2 25 | $0.43 | $-0.04 | ||
| Q1 25 | $0.51 | $0.09 | ||
| Q4 24 | $0.08 | $-0.02 | ||
| Q3 24 | $0.17 | $-0.15 | ||
| Q2 24 | $0.02 | $-0.05 | ||
| Q1 24 | $0.21 | $0.07 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $74.5M | $1.4B |
| 総負債低いほど良い | $624.2M | — |
| 株主資本純資産 | $332.4M | $1.9B |
| 総資産 | $1.4B | $2.9B |
| 負債/資本比率低いほどレバレッジが低い | 1.88× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $74.5M | $1.4B | ||
| Q3 25 | $85.3M | $1.4B | ||
| Q2 25 | $77.0M | $1.6B | ||
| Q1 25 | $70.4M | $1.6B | ||
| Q4 24 | $67.1M | $1.6B | ||
| Q3 24 | $89.8M | $1.7B | ||
| Q2 24 | $114.6M | $1.9B | ||
| Q1 24 | $98.7M | $1.9B |
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $332.4M | $1.9B | ||
| Q3 25 | $311.7M | $1.7B | ||
| Q2 25 | $285.7M | $1.7B | ||
| Q1 25 | $266.0M | $1.8B | ||
| Q4 24 | $246.8M | $1.7B | ||
| Q3 24 | $258.5M | $1.8B | ||
| Q2 24 | $256.6M | $2.0B | ||
| Q1 24 | $270.1M | $2.0B |
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.4B | $2.6B | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.3B | $2.9B | ||
| Q4 24 | $1.3B | $2.7B | ||
| Q3 24 | $966.3M | $2.7B | ||
| Q2 24 | $982.2M | $2.8B | ||
| Q1 24 | $979.0M | $3.0B |
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.4M | $28.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $8.3M | $25.1M |
| FCFマージンFCF / 売上 | 2.2% | 6.1% |
| 設備投資強度設備投資 / 売上 | 3.0% | 0.8% |
| キャッシュ転換率営業CF / 純利益 | 0.70× | 0.14× |
| 直近12ヶ月FCF直近4四半期 | $47.3M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.4M | $28.3M | ||
| Q3 25 | $9.3M | $41.6M | ||
| Q2 25 | $21.3M | $119.0M | ||
| Q1 25 | $43.2M | $146.1M | ||
| Q4 24 | $3.1M | $28.1M | ||
| Q3 24 | $12.6M | $46.4M | ||
| Q2 24 | $28.4M | $100.0M | ||
| Q1 24 | $11.4M | $145.6M |
| Q4 25 | $8.3M | $25.1M | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | $106.2M | ||
| Q1 25 | $35.4M | $138.7M | ||
| Q4 24 | $-4.7M | $23.2M | ||
| Q3 24 | $3.0M | $45.0M | ||
| Q2 24 | $15.4M | $98.8M | ||
| Q1 24 | $1.7M | $141.8M |
| Q4 25 | 2.2% | 6.1% | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | 29.8% | ||
| Q1 25 | 10.2% | 32.7% | ||
| Q4 24 | -1.5% | 6.5% | ||
| Q3 24 | 1.2% | 14.2% | ||
| Q2 24 | 5.6% | 29.5% | ||
| Q1 24 | 0.6% | 35.0% |
| Q4 25 | 3.0% | 0.8% | ||
| Q3 25 | 3.8% | 0.0% | ||
| Q2 25 | 3.5% | 3.6% | ||
| Q1 25 | 2.2% | 1.7% | ||
| Q4 24 | 2.5% | 1.4% | ||
| Q3 24 | 3.7% | 0.4% | ||
| Q2 24 | 4.8% | 0.4% | ||
| Q1 24 | 3.7% | 0.9% |
| Q4 25 | 0.70× | 0.14× | ||
| Q3 25 | 0.35× | 26.25× | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 2.07× | 2.82× | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 37.80× | — | ||
| Q1 24 | 1.36× | 4.29× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
